Id |
Subject |
Object |
Predicate |
Lexical cue |
T119 |
0-45 |
Sentence |
denotes |
Progress of Pharmacological Research on HXZQC |
T120 |
46-241 |
Sentence |
denotes |
Modern pharmacological studies have found that HXZQC has antiviral, anti-inflammatory, and immune regulatory activities, improves gastrointestinal discomfort and other properties (see Table 3 ). |
T121 |
242-344 |
Sentence |
denotes |
Table 3 Pharmacological functions and clinical research on top 10 CPMs for the treatment of COVID-19. |
T122 |
345-433 |
Sentence |
denotes |
Drug name Pharmacological action Mechanism Clinical application Therapeutic efficacy |
T123 |
434-632 |
Sentence |
denotes |
HXZQC Regulate the immunity and improve the gastroenteric function Inhibits LPS and epithelial barrier disorder, stipulate expression of proinflammatory cytokine of macrophage (Wang et al., 2012). |
T124 |
633-740 |
Sentence |
denotes |
Improve thymus coefficient, spleen coefficient, immunoglobulin G (IgG) level of the mice (Li et al., 2017). |
T125 |
741-894 |
Sentence |
denotes |
Regulates effect of the balance of CD4+ and CD8+ T lymphocytes, and reduction of IL-2, IL-10, IL-1β and TNF-α level (He et al., 2006; Zong et al., 2015). |
T126 |
895-1051 |
Sentence |
denotes |
Improves serum NO level of rats, reduces concentration of 5-HT, and downregulates the level of plasma motilin and colonic somatostatin (Huang et al., 2016). |
T127 |
1053-1208 |
Sentence |
denotes |
Children with rotavirus enteritis Shortens anti-diarrheal time and total course of time in treating children with rotavirus enteritis (Ma and Wang, 2012). |
T128 |
1209-1307 |
Sentence |
denotes |
Anti-virus Inhibits Avian Influenza Virus H5N1 regulating the gastrointestinal tract (Liu, 2009). |
T129 |
1309-1429 |
Sentence |
denotes |
Influenza Extends relief time of fever symptom, relieves time of muscle aches and relieves time of fatigue (Han, 2016). |
T130 |
1430-1752 |
Sentence |
denotes |
Inhibition effect of vibrio parahaemolyticus, Candida albicans, staphylococcus aureus and diplococcus pneumonia (Zhang, 2013) – Cold Relieves fever, nasal congestion, running nose, spontaneous sweating, headache, cough and spitting, fatigue and weakness, body ache and other cold symptoms (Wu, 2010; Zhao et al., 2017). |
T131 |
1753-1828 |
Sentence |
denotes |
Acute gastro-enteritis Improves total response rate and clinical symptoms. |
T132 |
1829-2088 |
Sentence |
denotes |
LHQWC Anti-virus Inhibits proliferation of influenza virus and regulates immune response to viral infection (Ding et al., 2017; Yao et al., 2020).Inhibits SARS-CoV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro (Li R. |
T133 |
2089-2106 |
Sentence |
denotes |
F. et al., 2020). |
T134 |
2108-2602 |
Sentence |
denotes |
COVID-19 Improves the fever, weakness, cough, short breath, chest distress, anorexia and other clinical symptoms of COVID-19, reduces the ratio of common to severe (Cheng et al., 2020; Hu et al., 2020; Lyu et al., 2020).Lianhua Qingwen granule combined with Abidole can effectively relieve clinical symptoms of mild COVID-19 patients, regulate expression of related inflammatory factors, improve the curative effect and reduce the rate of severe illness (Liu et al., 2020; Yu P. et al., 2020). |
T135 |
2603-2743 |
Sentence |
denotes |
Anti-acute lung injury Inhibits expression and secretion level of MCP-1, reduces infiltration of mononuclear macrophages (Li et al., 2019). |
T136 |
2744-2892 |
Sentence |
denotes |
Reduces LDH and MDA level, increases content of GSH-Px, and relieves the exudation of inflammatory cells in the alveolar cavity (Ping et al., 2016). |
T137 |
2893-2972 |
Sentence |
denotes |
Downregulates expression of IKK/IκB/NF-κB signaling pathway (Cui et al., 2016). |
T138 |
2973-3147 |
Sentence |
denotes |
Reduces protein expression and mRNA expression of inflammatory cytokines in lung tissues through reducing content of inflammatory cytokines in mice blood (Tang et al., 2015). |
T139 |
3149-3331 |
Sentence |
denotes |
H1N1 Improves cough, sore throat, body ache and other symptoms of the patients infected with H1N1 virus, and reduces the duration of fever (Duan et al., 2011; Zhao P. et al., 2014). |
T140 |
3332-3484 |
Sentence |
denotes |
Influenza LHQWC has better total response rate, symptom improvement rate and body temperature recovery rate than the control group (Wang et al., 2019). |
T141 |
3485-3650 |
Sentence |
denotes |
URI Improves the patients’ nasal congestion, fever, headache, sore throat, weakness, aches in the limbs, intolerance of cold and other clinical symptoms (Li, 2019). |
T142 |
3651-3800 |
Sentence |
denotes |
Chronic obstructive pulmonary Improves the condition of the patients with AECOPD, and reduces release of inflammatory mediators (Dong et al., 2014). |
T143 |
3801-3951 |
Sentence |
denotes |
JHQGG Anti-virus Decreases average level of CRP and IFN-γ in serum of the influenza patients, and decreases inflammatory response (Qi et al., 2016). |
T144 |
3953-4039 |
Sentence |
denotes |
COVID-19 Alleviates symptoms of fever, cough, fatigue and sputum (Duan et al., 2020). |
T145 |
4040-4095 |
Sentence |
denotes |
H1N1 Shortens antipyretic time (Wang C. et al., 2011). |
T146 |
4096-4214 |
Sentence |
denotes |
Influenza Reduces the serum levels of cytokines and improve their immune function (Li et al., 2013; Qi et al., 2016). |
T147 |
4215-4481 |
Sentence |
denotes |
SFJDC Anti-virus Improves mice pneumonia symptoms caused by influenza virus, reduce lung index of the mice infected with H1N1, and significantly reduces mortality rate of the infected animals (Liu et al., 2010; Lv et al., 2013; Qiu et al., 2014; Bao et al., 2019). |
T148 |
4483-4552 |
Sentence |
denotes |
Acute URI + fever Improves respiratory symptoms (Wang and Qiu, 2018) |
T149 |
4553-4721 |
Sentence |
denotes |
Anti-inflammation Reduces the WBC count, and reduces the serum transcription factor NF-κB, chemokine MCP-1, inflammatory mediator BK and COX-2 level (Ma et al., 2018). |
T150 |
4723-4865 |
Sentence |
denotes |
CAP Shortens recover time of multiple symptoms and signs such as fever, reduces levels of PCT, CRP and WBC and other indicators (Wang, 2016). |
T151 |
4866-5097 |
Sentence |
denotes |
Immune-regulation Reduces levels of B lymphocytes, CD8+ proportion, IL-1α, IL-1β, IL-2, IgM, IgG, etc., reduces quality of thymus, spleen and lung of pneumonia mice, and increase CD4+/CD8+ and NK cell proportion (Ma et al., 2019). |
T152 |
5099-5156 |
Sentence |
denotes |
AECOPD Reduces levels of IL-8, TNF-α, CRP and PCT (Yu H. |
T153 |
5157-5225 |
Sentence |
denotes |
X. et al., 2020) and increases arterial blood gas PaO2 (Wang, 2015). |
T154 |
5226-5362 |
Sentence |
denotes |
Anti-acute lung injury Inhibition of the MAPK/NF-κB signaling pathway, and down-regulation of NF-κB mRNA expression (Tao et al., 2014). |
T155 |
5363-5444 |
Sentence |
denotes |
The action might be closely related with ERK signaling pathway (Li et al., 2017). |
T156 |
5446-5626 |
Sentence |
denotes |
Bacterial acute bronchitis and Pneumonia Shortens recovery time of body temperature, duration of cough and the course of treatment, and increases oxygen index (Wang et al., 2014). |
T157 |
5627-5779 |
Sentence |
denotes |
TRQI Anti-virus Inhibition of intracellular proliferation and enhancement of body immunity of mice infected with influenza virus (Zheng and Gu, 2009). |
T158 |
5780-5928 |
Sentence |
denotes |
Destroys MRSA biofilm, and induces its death, and when in combined use with vancomycin or linezolid below the MIC concentration (Yang et al., 2018). |
T159 |
5930-6054 |
Sentence |
denotes |
Viral pneumonia A systematic review: TRQI had advantages in response rate of treatment, average length of stay (Pan, 2016). |
T160 |
6055-6124 |
Sentence |
denotes |
Anti-bacteria Destroys the bacterial biofilm (Wang Y. et al., 2011). |
T161 |
6126-6245 |
Sentence |
denotes |
Acute bronchitis Improves response rate, reduce fever, cough, crackles and X-ray shadow absorption (Wang et al., 2016) |
T162 |
6246-6426 |
Sentence |
denotes |
Anti-inflammation Inhibits release of inflammatory factors such as TNF-α, IL-6 and NO, and inhibits airway inflammation caused by LPS through MAPK/NF-B pathway (Liu et al., 2016). |
T163 |
6428-6510 |
Sentence |
denotes |
Acute attack of chronic bronchitis Improves clinical symptoms (Gao et al., 2019). |
T164 |
6511-6639 |
Sentence |
denotes |
Anti-airway mucus hypersecretion Regulates the IL-17 signaling pathway and its downstream protein MUC5AC (Liu W. et al., 2019). |
T165 |
6641-6846 |
Sentence |
denotes |
CAP Improves clinical effect and the symptom of cough with expectoration, shortens the duration of fever and promotes shadow absorption on chest radiography and the hemogram recovery (Jiang et al., 2009). |
T166 |
6847-7003 |
Sentence |
denotes |
Anti-acute lung injury Improves blood flow status of capillaries in the alveolar walls while repressing LPS-induced inflammatory cascade (Li et al., 2005). |
T167 |
7005-7224 |
Sentence |
denotes |
Tuberculosis accompanied by infection A systematic review: TRQI might have the same overall effect with some antibacterial drugs in treating patients with tuberculosis accompanied by lung infection (Lian et al., 2018). |
T168 |
7225-7376 |
Sentence |
denotes |
AECOPD Reduction of the patients’ serum IL-8 and NE level, and improvement of airway inflammation reaction and mucus hypersecretion (Li et al., 2010). |
T169 |
7377-7528 |
Sentence |
denotes |
A systematic review: improves clinical effect and lung function of AECOPD patients, reduces pCO2, and shortens the length of stay (Zhong et al., 2010). |
T170 |
7529-7610 |
Sentence |
denotes |
XYPI Anti-virus Inhibits proliferation of human rhinovirus in mice (Liu, 2015). |
T171 |
7612-7716 |
Sentence |
denotes |
Viral pneumonia Increases the cure rate, and improve the symptoms and signs (Li, 2015; Qi et al., 2018) |
T172 |
7717-8018 |
Sentence |
denotes |
Anti-acute lung injury Inhibits release of proinflammatory cytokines such as IL-10, IL4, etc., and could promote the proinflammatory cytokines/anti-inflammatory cytokines to tend to be balanced, and inhibit excess anti-inflammatory responses during the course of acute lung injury (Nie et al., 2012). |
T173 |
8020-8279 |
Sentence |
denotes |
Severe pneumonia Shortens the course of disease, improves the treatment efficiency, reduces incidence rate of antibiotic resistance, reduces occurrence of double infection, further improves the prognosis and reduces the mortality rate (Zhang and Wang, 2015). |
T174 |
8280-8511 |
Sentence |
denotes |
Reduces leukocytes, improve oxygen index, lower CPIS score, promotes absorption of pulmonary inflammation, shortens the duration of mechanical ventilation and length of stay in ICU, and improves clinical effect (Yang et al., 2014). |
T175 |
8512-8687 |
Sentence |
denotes |
Inhibition effect of staphylococcus aureus and pneumonia streptococcus (Yu et al., 2009) – Upper respiratory infection Improves symptoms of the patients (Liu and Li, 2015). |
T176 |
8688-8842 |
Sentence |
denotes |
XBJI Anti-inflammation Downregulates expression of inflammatory cytokines stimulated by Pam3CSK4 and activating MAPK, PI3K/Akt and other pathways (Li T. |
T177 |
8843-8860 |
Sentence |
denotes |
T. et al., 2020). |
T178 |
8861-9062 |
Sentence |
denotes |
Reduces TNF-α, IL-6 and IL-10 level of mice with sepsis, prevents the neutrophils from infiltrating the lung and kidney, inhibit Th1/Th2, Th17 and Tregs balance (Zhang et al., 2006; Chen et al., 2018). |
T179 |
9064-9169 |
Sentence |
denotes |
COVID-19 Improves the inflammatory markers and prognosis of severe COVID-19 patients (Wen et al., 2020). |
T180 |
9170-9306 |
Sentence |
denotes |
SIRS Expression of CD4+, CD4+/CD8+, CD14+/HLA-DR increased, and improves systematic status of the SIRS patients (Zhao W. et al., 2014). |
T181 |
9307-9508 |
Sentence |
denotes |
Severe pneumonia Reduces the level of inflammatory factors, improves the total treatment efficiency (Qi et al., 2011), reduces infectious indicators and the average length of stays (Zhu et al., 2014). |
T182 |
9509-9658 |
Sentence |
denotes |
Anti-acute lung injury Reduces TNF-α level, alleviates the degree of pulmonary tissue edema and inflammatory cell infiltration (Zhang et al., 2014). |
T183 |
9660-9825 |
Sentence |
denotes |
SCAP Improves primary endpoint-pneumonia severity index, reduces mortality rate in 28 days, and shortens the duration of mechanical ventilation (Song et al., 2019). |
T184 |
9826-10028 |
Sentence |
denotes |
Immune-regulation Blocks p-38 MAPK and NF-κB 65 pathways (Liu et al., 2014); reduces IL-1, IL-6 and TNF-α level, improves CD4+/CD8+ T lymphocyte ratio and NK cell relative activity (Teng et al., 2012). |
T185 |
10030-10218 |
Sentence |
denotes |
AECOPD Lowers the inflammatory indicators, improve cough, expectoration, short breath and other clinical symptoms, and shortens their length of stay (Chen et al., 2011; Zhu et al., 2019). |
T186 |
10219-10297 |
Sentence |
denotes |
Anti-oxidation Improves activity of SOD, reduce ROS level (Jin et al., 2018). |
T187 |
10298-10337 |
Sentence |
denotes |
Downregulates MDA (Luo and Zhou, 2017). |
T188 |
10339-10454 |
Sentence |
denotes |
Sepsis Reduces mortality rate of sepsis patients in 28 days, the APACHE-II and body temperature (Li et al., 2018). |
T189 |
10455-10629 |
Sentence |
denotes |
SFI Anti-acute lung injury Increases the wet/dry weight ratio of lung tissues, neutrophil ratio in BALF, protein content, lung tissue MDA and serum NO (Lin and Zhan, 2010). |
T190 |
10630-10691 |
Sentence |
denotes |
Reduces activation of NF-κB of lung tissue (Ai et al., 2006). |
T191 |
10692-10807 |
Sentence |
denotes |
Reduces expression level of p65, P50 mRNA and protein in lung tissues and TNF-α level in serum (Liu et al., 2019a). |
T192 |
10809-10935 |
Sentence |
denotes |
Sepsis Lowers IL-6 level, regulate balance between pro-inflammatory factors and anti-inflammatory factors (Qiu et al., 2012). |
T193 |
10936-11061 |
Sentence |
denotes |
Increases CD4+ and CD8+T cell counts in peripheral blood and upregulated HLA-DR expression in monocytes (Zhang et al., 2017). |
T194 |
11062-11172 |
Sentence |
denotes |
Anti-shock Increases content of ATP and taurine, and reduces content of AMP in the heart (Liu et al., 2019b). |
T195 |
11174-11261 |
Sentence |
denotes |
Severe pneumonia of elderly Decreases level of TNF-α, IL-6 and IL-8 (Lv et al., 2017). |
T196 |
11262-11381 |
Sentence |
denotes |
Acute lung injury Improves respiratory rate, oxygen index, and lowers the ICAM-1, ET-1 and NO level (Ma et al., 2019). |
T197 |
11382-11502 |
Sentence |
denotes |
Respiratory failure Improves serum prealbumin, oxygen index, shortens the duration of mechanical ventilation (Li, 2013) |
T198 |
11503-11641 |
Sentence |
denotes |
SMI Improve pulmonary function Raises NO level, dropping oxygen free radical levels and decreases lipid peroxidation (Lin et al., 2007). |
T199 |
11642-11725 |
Sentence |
denotes |
Lowers expression of NF-κB and activity of iNOS in lung tissues (Liu et al., 2009). |
T200 |
11727-11852 |
Sentence |
denotes |
COPD Improves pulmonary function index, blood gas index, IgG index and disappearance time of lung rale (Huang et al., 2019). |
T201 |
11853-11932 |
Sentence |
denotes |
Anti-inflammation Inhibits expression of ICAM-1 and VCAM-1 (Liu et al., 2015). |
T202 |
11933-12079 |
Sentence |
denotes |
Inhibits generation of inflammatory cytokines of ischemia-reperfusion rats, lowers expression level of TNF-α, IL-6, IL-8, etc. (Wang et al., 2015) |
T203 |
12080-12142 |
Sentence |
denotes |
Immune-regulation Inhibits monocyte MCP-1 (Liu et al., 2015). |
T204 |
12143-12286 |
Sentence |
denotes |
Increases the content of serum immunoglobulin IgG and the number of T cells, enhances the phagocytic function of macrophages (Du et al., 2001). |
T205 |
12288-12485 |
Sentence |
denotes |
Prevent inflammatory response Improves microcirculation, protect the organ functions, and prevents further occurrence and development of systemic inflammatory response syndrome (Guo et al., 2004). |
T206 |
12486-12619 |
Sentence |
denotes |
Improve pulmonary function Raises NO level, dropping oxygen free radical levels and decreases lipid peroxidation (Lin et al., 2007). |
T207 |
12620-12703 |
Sentence |
denotes |
Lowers expression of NF-κB and activity of iNOS in lung tissues (Liu et al., 2009). |
T208 |
12704-12870 |
Sentence |
denotes |
AGNHP Anti-inflammation Inhibits release of superoxide radical; reverses changes in cortical monoamine neurotransmitters (Zhang F. et al., 2010; Zhu and Sun, 2014). |
T209 |
12871-12954 |
Sentence |
denotes |
Lowers serum LPS level and lung myeloperoxidase (MPO) content (Zhang et al., 2009). |
T210 |
12955-13038 |
Sentence |
denotes |
Lowers total LDH activity, and changes percentage of isomerase (Tang et al., 2005). |
T211 |
13040-13285 |
Sentence |
denotes |
Hyperpyrexia, coma caused by severe infectious diseases Promotes consciousness, improves the neurologic function (Feng and Yang, 2015), shortens average defervescence time (Long and Wu, 2014) and moderates effect on Th1/Th2 (Ma and Zhou, 2015). |
T212 |
13286-13450 |
Sentence |
denotes |
Viral encephalitis Reduces body temperature, avoids convulsion, promotes consciousness, and alleviates cerebral edema and brain cell damage (Zhang and Dong, 2014). |
T213 |
13451-13704 |
Sentence |
denotes |
Neuroprotective effect Regulates Th17/Treg balance, inhibits chronic inflammation, reduces plaque collagen fibers, and reduces inflammatory cells infiltration (Fan et al., 2020) Pneumonia Reduces PCT and improves immune function (Zhuo and Wen, 2017). |
T214 |
13705-13807 |
Sentence |
denotes |
Antipyretic and analgesic – ACI intracerebral hemorrhage Neuroprotective effect (Han et al., 2019). |
T215 |
13808-14056 |
Sentence |
denotes |
Research by Zhonghua Liu et al. (Liu, 2009) revealed that HXZQC inhibited the lung index of mice infected with avian influenza virus (AIV) H5N1, reduced the development of lung disease, and enhanced the antiviral capacity of mice infected with AIV. |
T216 |
14057-14190 |
Sentence |
denotes |
The death rate of the infected mice was reduced through regulation of the gastrointestinal tract and strengthening of the stomach Qi. |
T217 |
14191-14351 |
Sentence |
denotes |
Hongkun Zhang (Zhang, 2013) found that HXZQC inhibited growth of Vibrio parahaemolyticus, Candida albicans, Staphylococcus aureus, and Streptococcus pneumoniae. |
T218 |
14352-14633 |
Sentence |
denotes |
Research by Wang et al. (2012) found that HXZQC inhibited lipopolysaccharide (LPS)-stimulated expression of proinflammatory cytokines by macrophages and inhibited epithelial barrier disorder induced by interferon-γ (IFN-γ), regulating immunity and improving gastroenteric function. |
T219 |
14634-14896 |
Sentence |
denotes |
Research by Chunyuan Li et al. (Li et al., 2017) showed that HXZQC significantly improved the thymus coefficient, spleen coefficient and immunoglobulin G (IgG) levels of mice with dampness obstructing spleen-stomach, and enhanced the immune function of the mice. |
T220 |
14897-15226 |
Sentence |
denotes |
Studies by Yinghui He et al. (He et al., 2006) and Shaobo Zong et al. (Zong et al., 2015) discovered that HXZQC had therapeutic effects in mice with Bacillus dysenteriae and Salmonella typhimurium-induced diarrhea (BSD mice), mice with bacterial enteritis, and model rats with diarrhea-predominant irritable bowel syndrome (IBS). |
T221 |
15227-15485 |
Sentence |
denotes |
Clinical symptoms were significantly improved, which might be due to effects on the balance of CD4+ and CD8+ T lymphocytes, and reduction of interleukin-2 (IL-2), interleukin-10 (IL-10), interleukin-1β (IL-1β), and tumor necrosis factor alpha (TNF-α) levels. |
T222 |
15486-15645 |
Sentence |
denotes |
The results suggested that HXZQC, via immune-regulation and anti-inflammatory activity, could have therapeutic effects against many gastrointestinal disorders. |
T223 |
15646-15858 |
Sentence |
denotes |
Research by Hefei Huang et al. (Huang et al., 2016) showed that HXZQC extracts had a positive regulatory effect on intestinal dysfunction, and had therapeutic efficacy in model rats with diarrhea-predominant IBS. |
T224 |
15859-16014 |
Sentence |
denotes |
Efficacy was mediated by improving serum NO levels and reducing the concentrations of 5-hydroxytryptamine (5-HT), plasma motilin, and colonic somatostatin. |